Erika D. Lease
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erika D. Lease has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen J. Ramos
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington
5 shared publications - Siddhartha G. Kapnadak
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
5 shared publications Christopher H. Goss
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle WA, United States; Division of Pulmonary and Allergy, Department of Pediatrics, University of Washington, Seattle WA, United States; CFF TDNCC Seattle Children's Research Institute, Seattle, WA, United States
4 shared publications- Robert M. Rakita
Division of Allergy and Infectious Diseases University of Washington Seattle Washington USA
4 shared publications - Carli J. Lehr
Cleveland Clinic
3 shared publications - Madeleine R. Heldman
Division of Infectious Diseases Department of Medicine Duke University School of Medicine Durham North Carolina USA
3 shared publications
Latest Publications
- 21 September 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (10) , 1529-1531
Baseline Lung Allograft Dysfunction: Definition, Timing, and Implications for Outcomes—Perspective on the ISHLT Consensus Document
- 21 September 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (10) , 1529-1531
Baseline Lung Allograft Dysfunction: Definition, Timing, and Implications for Outcomes—Perspective on the ISHLT Consensus Document
- 31 August 2025
- Published by Springer Nature
- p. 173-192
Primary Care of the Adult Lung Transplant Recipient
- 31 August 2025
- Published by Springer Nature
- p. 173-192
Primary Care of the Adult Lung Transplant Recipient
- 2 July 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (5) , 929-934
Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US
- 2 July 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (5) , 929-934
Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US
- Open Access
Airway complications after lung transplantation: Perioperative risk factors and clinical outcomes
- 30 September 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 175, 111514
Corrigendum to “Development of an international glossary for clinical guidelines collaboration” “[Journal of Clinical Epidemiology 158 (2023) 84-91]”
- 30 September 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 175, 111514
Corrigendum to “Development of an international glossary for clinical guidelines collaboration” “[Journal of Clinical Epidemiology 158 (2023) 84-91]”
- 1 February 2024
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (2) , 271-278
Lung Allocation Score Exceptions in Persons with Cystic Fibrosis Undergoing Lung Transplant
Rationale: Lung transplantation can extend the lives of individuals with advanced cystic fibrosis (CF). Until March 2023, the Lung Allocation Score (LAS) was used in the United States to determine transplant priority. Certain clinical events or attributes (“risk events”) that are not included in the LAS (e.g., massive hemoptysis) are relatively common and prognostically important in CF and may prompt an exception request to increase priority for donor lungs. The new Lung Composite Allocation Score (CAS) also allows for exceptions based on the same principles. Objectives: To evaluate the frequency of LAS exceptions in persons with CF (PwCFs) listed for lung transplantation and assess whether LAS exceptions are associated with improved waitlist outcomes for PwCFs compared with similarly “at-risk” individuals without LAS exceptions. Methods: A merged dataset combining data from the CF Foundation Patient Registry and the Organ Procurement and Transplantation Network (2005–2019) was used to identify PwCFs listed for lung transplantation. We compared waitlist outcomes between PwCFs with a LAS exception versus those without an exception despite having a risk event. Risk events were defined as an episode of massive hemoptysis, pneumothorax, at least three moderate/severe pulmonary exacerbations, and/or a decrease in forced expiratory volume in 1 second by ⩾30% predicted (absolute) in the prior 12 months. Analyses were performed using competing risk regression with time to transplantation as the primary outcome and death without a transplant as a competing risk. Results: Of 3,538 listings from 3,309 candidates, 2% of listings (n = 81) had at least one exception. Candidates with an exception and those with a risk event but no exception received lung transplants more slowly than people without an exception or risk event (subdistribution hazard ratio [95% confidence interval]: LAS exception cohort, 0.66 [0.52–0.85]; risk event cohort without exceptions, 0.79 [0.72–0.86]). There was no difference between those with LAS exceptions and those at risk without LAS exceptions: subdistribution hazard ratio, 0.84 (0.66–1.08). Conclusions: LAS exceptions are rare in PwCFs listed for lung transplantation. LAS exceptions resulted in a similar time to transplantation for PwCFs compared with similarly at-risk individuals. As we enter the CAS era, these LAS-based results are pertinent to improve risk stratification among PwCFs being considered for lung transplantation.
- 1 February 2024
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (2) , 271-278
Lung Allocation Score Exceptions in Persons with Cystic Fibrosis Undergoing Lung Transplant
Rationale: Lung transplantation can extend the lives of individuals with advanced cystic fibrosis (CF). Until March 2023, the Lung Allocation Score (LAS) was used in the United States to determine transplant priority. Certain clinical events or attributes (“risk events”) that are not included in the LAS (e.g., massive hemoptysis) are relatively common and prognostically important in CF and may prompt an exception request to increase priority for donor lungs. The new Lung Composite Allocation Score (CAS) also allows for exceptions based on the same principles. Objectives: To evaluate the frequency of LAS exceptions in persons with CF (PwCFs) listed for lung transplantation and assess whether LAS exceptions are associated with improved waitlist outcomes for PwCFs compared with similarly “at-risk” individuals without LAS exceptions. Methods: A merged dataset combining data from the CF Foundation Patient Registry and the Organ Procurement and Transplantation Network (2005–2019) was used to identify PwCFs listed for lung transplantation. We compared waitlist outcomes between PwCFs with a LAS exception versus those without an exception despite having a risk event. Risk events were defined as an episode of massive hemoptysis, pneumothorax, at least three moderate/severe pulmonary exacerbations, and/or a decrease in forced expiratory volume in 1 second by ⩾30% predicted (absolute) in the prior 12 months. Analyses were performed using competing risk regression with time to transplantation as the primary outcome and death without a transplant as a competing risk. Results: Of 3,538 listings from 3,309 candidates, 2% of listings (n = 81) had at least one exception. Candidates with an exception and those with a risk event but no exception received lung transplants more slowly than people without an exception or risk event (subdistribution hazard ratio [95% confidence interval]: LAS exception cohort, 0.66 [0.52–0.85]; risk event cohort without exceptions, 0.79 [0.72–0.86]). There was no difference between those with LAS exceptions and those at risk without LAS exceptions: subdistribution hazard ratio, 0.84 (0.66–1.08). Conclusions: LAS exceptions are rare in PwCFs listed for lung transplantation. LAS exceptions resulted in a similar time to transplantation for PwCFs compared with similarly at-risk individuals. As we enter the CAS era, these LAS-based results are pertinent to improve risk stratification among PwCFs being considered for lung transplantation.
- Open Access
- 1 November 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 208 (9) , 951-952
Time Matters: Understanding the Dynamic Nature of Disease Trajectory to Better Allocate Donor Lungs
- 1 November 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 208 (9) , 951-952
Open AccessTime Matters: Understanding the Dynamic Nature of Disease Trajectory to Better Allocate Donor Lungs
- 3 October 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 545-548
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant
- 3 October 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 545-548
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant